Clene Inc. (CLNN)

Last Closing Price: 3.52 (2026-11-20)

Company Description

Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $0.20M
Net Income (Most Recent Fiscal Year) $-26.17M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 221.45
Price to Book Ratio (Most Recent Quarterly Book Value per Share) --
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -11271.43%
Net Margin (Trailing 12 Months) -11274.79%
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) -77.56%
Current Ratio (Most Recent Fiscal Quarter) 0.85
Quick Ratio (Most Recent Fiscal Quarter) 0.84
Debt to Common Equity (Most Recent Fiscal Quarter) --
Inventory Turnover (Trailing 12 Months) 1.78
Book Value per Share (Most Recent Fiscal Quarter) $-1.03
Earnings per Share (Most Recent Fiscal Quarter) $0.05
Earnings per Share (Most Recent Fiscal Year) $-3.06
Diluted Earnings per Share (Trailing 12 Months) $-2.60
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 14.40M
Free Float 10.32M
Market Capitalization $52.71M
Average Volume (Last 20 Days) 0.09M
Beta (Past 60 Months) 1.04
Percentage Held By Insiders (Latest Annual Proxy Report) 28.30%
Percentage Held By Institutions (Latest 13F Reports) 23.28%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%